Taiwan's TWi Pharmaceutical said CEO and president Tina Guilder has resigned, making it less than a year since she joined from Teva Pharmaceuticals ($TEVA) after the company broke with the Israeli firm on U.S. marketing plans in March. She will be replaced by Chairman Chih-Ming Chen as interim president and CEO. "Taking the CEO role personally, he will focus on operating strategies, making precise product selections, motivating top management and all employees, and integrating the business groups' resources to strengthen the core competencies of TWi," the company said in a release. In August, the company said it has received Notices of Allowance for lead candidate AC-201, a first-in-class small molecule, from the European Patent Office and the Patent Office of the Russian Federation. In May, TWi Pharmaceutical promoted its R&D executive vice president Jianbo Xie to chief operating officer. Release